These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 32387009)
1. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009 [TBL] [Abstract][Full Text] [Related]
2. HPV genoprevalence and HPV knowledge in young women in Mongolia, five years following a pilot 4vHPV vaccination campaign. Batmunkh T; von Mollendorf C; Tulgaa K; Surenjav U; Dalmau MT; Namjil N; Tsedevdamba B; Tsegmed S; Enkhmaa J; Garland SM; Mulholland K Papillomavirus Res; 2019 Dec; 8():100175. PubMed ID: 31276802 [TBL] [Abstract][Full Text] [Related]
3. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422 [TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction. Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743 [TBL] [Abstract][Full Text] [Related]
5. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886 [TBL] [Abstract][Full Text] [Related]
6. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN; Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506 [TBL] [Abstract][Full Text] [Related]
7. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680 [TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300 [TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario. Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207 [TBL] [Abstract][Full Text] [Related]
10. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ; MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963 [TBL] [Abstract][Full Text] [Related]
12. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901 [TBL] [Abstract][Full Text] [Related]
13. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM; Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women. Winer RL; Lin J; Querec TD; Unger ER; Stern JE; Rudd JM; Golden MR; Swanson F; Markowitz LE; Meites E J Infect Dis; 2022 Feb; 225(3):422-430. PubMed ID: 34320185 [TBL] [Abstract][Full Text] [Related]
15. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination. Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217 [TBL] [Abstract][Full Text] [Related]
16. Acceptance of Self-Sampling and Knowledge about Human Papillomavirus among Women in Mongolia. Batmunkh T; Surenjav U; Namjil N; Dorj G; Sambuu T; Amraa O Asian Pac J Cancer Prev; 2024 May; 25(5):1823-1829. PubMed ID: 38809655 [TBL] [Abstract][Full Text] [Related]
17. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018. Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964 [TBL] [Abstract][Full Text] [Related]
18. HPV cervical infections and serological status in vaccinated and unvaccinated women. Murall CL; Reyné B; Selinger C; Bernat C; Boué V; Grasset S; Groc S; Rahmoun M; Bender N; Bonneau M; Foulongne V; Graf C; Picot E; Picot MC; Tribout V; Waterboer T; Bravo IG; Reynes J; Segondy M; Boulle N; Alizon S Vaccine; 2020 Dec; 38(51):8167-8174. PubMed ID: 33168348 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France. Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I; J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911 [TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study. Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T Front Public Health; 2023; 11():1204101. PubMed ID: 37719724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]